<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="4717">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on February 08, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04349332</url>
  </required_header>
  <id_info>
    <org_study_id>20-0594</org_study_id>
    <nct_id>NCT04349332</nct_id>
  </id_info>
  <brief_title>Early Extubation for Patients With Acute Hypoxemic Respiratory Failure</brief_title>
  <official_title>Early Extubation for Patients With Acute Hypoxemic Respiratory Failure</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Chicago</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Chicago</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of the study is to evaluate the efficacy of helmet NIV in reducing the duration&#xD;
      of invasive mechanical ventilation in order to minimize ventilator needs during the COVID-19&#xD;
      pandemic.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Single center randomized clinical trial investigating the efficacy of helmet NIV used for&#xD;
      early liberation from mechanical ventilation in patients with acute hypoxemic respiratory&#xD;
      failure.&#xD;
&#xD;
      Intervention: Helmet group Patients randomized to the intervention group will be extubated to&#xD;
      helmet NIV without a spontaneous breathing trial. The helmet will be connected to oxygen and&#xD;
      room air flow meter to deliver a minimum of 60L of fresh gas flow and a PEEP valve. The PEEP&#xD;
      will be increased using a PEEP valve in increments of 2-3 cmH20 to improve peripheral oxygen&#xD;
      saturation of at least 90% at an inspired oxygen requirement (FiO2) of ≤ 60%.14 After&#xD;
      application of the helmet, arterial blood gas sampling will be utilized to follow&#xD;
      gas-exchange; this is a part of usual care for the management of patients with acute&#xD;
      hypoxemic respiratory failure. Noninvasive support will be reduced progressively in&#xD;
      accordance to clinical improvement and will be discontinued if patient maintains respiratory&#xD;
      rate &lt;30breaths/min and PaO2 &gt;75mm Hg with FiO2 0.5 without ventilatory support. If&#xD;
      endotracheal intubation is required, the helmet will be removed and the patient will be&#xD;
      intubated without delay.&#xD;
&#xD;
      Control: Usual Care Patient randomized to the control group will continue invasive mechanical&#xD;
      ventilation until the following weaning criteria are met:15 Resolution or improvement of the&#xD;
      condition leading to intubation Hemodynamic stability, defined as systolic blood pressure&#xD;
      between 90 and 160 mm Hg and heart rate less than 140/min without vasopressors or with low&#xD;
      doses of vasopressors Glasgow Coma Scale score of 13 or greater Respiratory stability (oxygen&#xD;
      saturation &gt;90% with fraction of inspired oxygen [Fio2] ≤0.4, respiratory rate &lt;35/min,&#xD;
      Noncopious secretions (&lt;3 aspirations in the last 8 hours).&#xD;
&#xD;
      Once weaning criteria are met, patients will undergo a spontaneous breathing trial for 30&#xD;
      minutes on pressure support mode. Criteria for failure to tolerate the SBT were agitation,&#xD;
      anxiety, low level of consciousness (Glasgow Coma Scale score &lt;13), respiratory rate higher&#xD;
      than 35/min and/or use of accessory muscles, oxygen saturation by pulse oximetry less than&#xD;
      90% with Fio2 higher than 0.5, heart rate higher than 140/min or greater than a 20% increase&#xD;
      from baseline, systolic blood pressure lower than 90 mm Hg, or development of arrhythmia. If&#xD;
      the spontaneous breathing trial is successful, then the patient will be extubated.&#xD;
&#xD;
      Subjects will be followed for long term followup at 90 day and 1year mortality&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">August 13, 2020</start_date>
  <completion_date type="Anticipated">June 1, 2021</completion_date>
  <primary_completion_date type="Anticipated">April 1, 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>randomized trial</intervention_model_description>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>ventilator days</measure>
    <time_frame>up to 4 weeks</time_frame>
    <description>duration of mechanical ventilation via endotracheal tube</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Intensive care unit (ICU) length of stay</measure>
    <time_frame>up to 6 weeks</time_frame>
    <description>number of days admitted to the ICU</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>need for re-intubation</measure>
    <time_frame>up to 6 weeks</time_frame>
    <description>number of patients requiring endotracheal intubation after extubation</description>
  </secondary_outcome>
  <other_outcome>
    <measure>hospital length of stay</measure>
    <time_frame>up to 6 weeks</time_frame>
    <description>number of days spent in hospital during enrollment hospitalization</description>
  </other_outcome>
  <other_outcome>
    <measure>hospital mortality</measure>
    <time_frame>up to 6 weeks</time_frame>
    <description>death from any cause during hospitalization time of enrollment</description>
  </other_outcome>
  <other_outcome>
    <measure>long term mortality</measure>
    <time_frame>up to 1 year</time_frame>
    <description>death from any cause 90 day, 1year</description>
  </other_outcome>
  <other_outcome>
    <measure>ICU related complications</measure>
    <time_frame>up to 6 weeks</time_frame>
    <description>including ventilator associated pneumonia, GI hemorrhage, DVT/PE, sacral decubitus ulcer, delirium, ICU acquired weakness</description>
  </other_outcome>
  <other_outcome>
    <measure>discharge location</measure>
    <time_frame>up to 90 days</time_frame>
    <description>measure the location (home, rehabilitation center, nursing home)</description>
  </other_outcome>
  <other_outcome>
    <measure>health care utilization</measure>
    <time_frame>up to 6 weeks</time_frame>
    <description>days alive and institution free</description>
  </other_outcome>
  <other_outcome>
    <measure>diaphragm ultrasound thickness</measure>
    <time_frame>up to 6 weeks</time_frame>
    <description>ultrasound measurement at end expiration: enrollment, pre extubation, post extubation</description>
  </other_outcome>
  <other_outcome>
    <measure>diaphragm thickening fraction</measure>
    <time_frame>up to 6 weeks</time_frame>
    <description>ultrasound measurement at end expiration and inspiration to calculate thickening fraction</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">108</enrollment>
  <condition>Mechanical Ventilation</condition>
  <condition>Corona Virus Infection</condition>
  <arm_group>
    <arm_group_label>Helmet non invasive ventilation (NIV)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients randomized to the intervention group will be extubated to helmet NIV.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control invasive mechanical ventilation</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Patients randomized to the control group will continue invasive mechanical ventilation. Once weaning criteria are met, patients will undergo a spontaneous breathing trial for 30 minutes. If the spontaneous breathing trial is successful, then the patient will be extubated.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Helmet non-invasive ventilation (NIV)</intervention_name>
    <description>After application of the helmet, arterial blood gas sampling will be utilized to follow gas-exchange; Noninvasive support will be reduced progressively in accordance to clinical improvement and will be discontinued if patient maintains respiratory rate &lt;30breaths/min and PaO2 &gt;75mm Hg with FiO2 0.5 without ventilatory support. If endotracheal intubation is required, the helmet will be removed and the patient will be intubated without delay.</description>
    <arm_group_label>Helmet non invasive ventilation (NIV)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        Age ≥18 years old on mechanical ventilation for at least 48 hours Positive End Expiratory&#xD;
        Pressure (PEEP) level between 8 to 13cm H20 The ratio between the partial pressure of&#xD;
        oxygen and fraction of inspired oxygen (PaO2/FiO2) between 150 and 300 mmHg with FiO2≤0.6&#xD;
        pH≥7.25 Respiratory rate (RR)≤30/min Adequate gag and cough reflex Ability to spontaneously&#xD;
        breathe&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        Hemodynamic instability (Systolic blood pressure &lt;90 or requiring &gt;2 vasoactive agents)&#xD;
        Tracheostomy Upper airway obstruction Pregnancy Elevated intracranial pressure Upper airway&#xD;
        obstruction Glasgow coma scale ≤ 8 Patients who refuse to undergo endotracheal intubation,&#xD;
        whatever the initial therapeutic approach&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Bhakti Patel, MD</last_name>
    <phone>773-702-6800</phone>
    <phone_ext>3349</phone_ext>
    <email>bpatel@medicine.bsd.uchicago.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Anne Pohlman, MSN</last_name>
    <phone>773-702-3804</phone>
    <email>apohlman@medicine.bsd.uchicago.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University of Chicago Medical Center</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60637</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Bhakti Patel, MD</last_name>
      <email>bpatel@medicine.bsd.uchicago.edu</email>
    </contact>
    <contact_backup>
      <last_name>Anne Pohlman, MSN</last_name>
      <email>apohlman@medicine.bsd.uchicago.edu</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2020</verification_date>
  <study_first_submitted>April 14, 2020</study_first_submitted>
  <study_first_submitted_qc>April 15, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">April 16, 2020</study_first_posted>
  <last_update_submitted>November 2, 2020</last_update_submitted>
  <last_update_submitted_qc>November 2, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">November 4, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>helmet interface NIV</keyword>
  <keyword>early extubation</keyword>
  <keyword>acute hypoxemic respiratory failure</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Coronavirus Infections</mesh_term>
    <mesh_term>Severe Acute Respiratory Syndrome</mesh_term>
    <mesh_term>Respiratory Insufficiency</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

